Clinical systems · Point-of-care EEG and seizure detection
Ceribell
Ceribell is a publicly traded medical technology company in Sunnyvale, California, whose headband EEG system lets ICU and emergency teams record brain activity in minutes and uses AI to flag nonconvulsive seizures and delirium, with 747 hospital accounts as of September 2026.
Strong fit
- ICUs and emergency departments that wait hours for an EEG technologist, especially at night and on weekends
- Community and critical access hospitals that transfer patients just to rule out a seizure
- Neurocritical care teams that want seizure and delirium monitoring on one device
Weak fit
- Epilepsy monitoring units that need full-montage video EEG to localize a seizure focus
- Outpatient neurology practices running routine scheduled EEGs
- Hospitals without a neurologist or remote reading service to review the recordings
Bottom line
Ceribell gives ICU and emergency teams a headband EEG they can place in minutes, with AI that flags seizures and, since late 2026, delirium. It is worth a close look for hospitals that cannot get a conventional EEG quickly, from large academic ICUs to critical access hospitals. It works as a fast screening and monitoring tool alongside full EEG, which is still needed to pinpoint where a seizure starts.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
Ceribell is used in intensive care units and emergency departments when a patient is confused, sedated, or unresponsive and a doctor needs to know whether the brain is seizing without visible convulsions. A nurse or physician places a headband on the patient, and a small recorder starts showing EEG data within minutes. Ceribell's AI watches the recording continuously and alerts the team to possible seizure activity, while a neurologist can review the recording remotely through Ceribell's secure online portal. The Ceribell homepage lists 95% sensitivity and 97% specificity for detecting status epilepticus.
The product fits hospitals that cannot staff EEG technologists around the clock. A conventional EEG can take hours to set up, and Ceribell's case is speed: an ER director at Pullman Regional Hospital, a critical access hospital in Washington state, said the team is alerted to seizure-like activity in 5 minutes or less. Its direct competitors are other rapid EEG systems such as Zeto and devices from Natus, plus the standard option of calling in a technologist for a full EEG. On price, Ceribell is at the premium end of hospital monitoring, with revenue split between product sales and recurring Clarity software subscriptions.
The main limit is coverage. A 2022 review of rapid response EEG notes that reduced-montage devices like Ceribell's headband are screening tools and lack the spatial detail to localize small focal abnormalities, so a full EEG still has a place. Ceribell is also in a patent fight: it filed an infringement action against Natus Medical in July 2025, according to its third quarter 2026 results.
Ceribell reported revenue of $29.3 million in the third quarter of 2026, up 30% from a year earlier, a 90% gross margin, and a net loss of $21.4 million, and it expects full-year 2026 revenue of $115 million to $117 million. The company has added delirium monitoring on the same headband, and CMS approved a new technology add-on payment of up to $2,171 per eligible Medicare case for it from October 1, 2026.
What clinicians say
What people like
"Ceribell looks like a headband; it's easy to use, and in 5 minutes or less, we are alerted if a patient is experiencing seizure-like activity." Pullman Regional Hospital
"This device gives us the opportunity to test different interventions in individual patients to see what works to reduce their delirium burden." GlobeNewswire
What people don't like
"These reduced montage RRLM-EEG devices are not designed to be a replacement for the conventional EEG with a complete 10–20 array." PubMed Central
Pricing
| Item | Detail |
|---|---|
| Model | Hospital contracts that combine Ceribell hardware and supplies with a recurring Clarity software subscription. In the third quarter of 2026, product revenue was $22.2 million and subscription revenue was $7.1 million. |
| Reimbursement | From October 1, 2026, CMS pays a new technology add-on payment of up to $2,171 per eligible Medicare inpatient case that uses the delirium monitoring solution. |
| What drives cost | The number of recorders, headband use per month, and the Clarity subscription level. |
Leadership
Jane Chao, PhDCo-founder, President and CEO- Josef Parvizi, MD, PhDCo-founder, Chief Medical Adviser and Director
- Raymond Woo, PhDChief Technology Officer
Recent news
- November 2026: Ceribell reported third quarter revenue of $29.3 million, up 30% from a year earlier, added a record 35 net new accounts for a total of 747, and raised its 2026 revenue outlook to $115 million to $117 million.
- November 2026: Ceribell launched its delirium monitoring solution commercially after a pilot at hospitals that already used its seizure detection, making the headband the first FDA-cleared device to aid delirium screening and monitoring.
- August 2026: CMS granted a new technology add-on payment of up to $2,171 per eligible Medicare case for the Delirium Monitor System, effective October 1, 2026.
- August 2026: Ceribell entered a new credit facility with up to $60 million in committed capital, a $30 million term loan and a $30 million revolving line.
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.